DETECTION OF MALIGNANT CELLS IN MARROW & PBPC FRACTIONS

骨髓中恶性细胞的检测

• 批准号: 2863385
• 负责人: Elizabeth J Shpall
• 金额: $ 13.3万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-09-08 至 2000-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2863385
• 关键词: antitumor antibody; bone marrow; breast neoplasm /cancer diagnosis; breast neoplasms; circulating neoplastic cell; clinical research; cooperative study; diagnosis design /evaluation; female; hematopoietic stem cells; human tissue; immunocytochemistry; keratin; minimal residual disease; monoclonal antibody; neoplasm /cancer epidemiology; neoplasm /cancer immunodiagnosis; polymerase chain reaction; women's health; antitumor antibody; bone marrow; breast neoplasm /cancer diagnosis; breast neoplasms; circulating neoplastic cell; clinical research; cooperative study; diagnosis design /evaluation; female; hematopoietic stem cells; human tissue; immunocytochemistry; keratin; minimal residual disease; monoclonal antibody; neoplasm /cancer epidemiology; neoplasm /cancer immunodiagnosis; polymerase chain reaction; women's health

The specific aims of this project are: 1. To determine the feasibility of assaying the marrow and peripheral blood progenitor cell (PBPC) fractions of breast cancer patients enrolled on S9623 for the presence of malignant cells; 2. To determine the feasibility of quantitating the breast cancer cell content of the marrow and PBPC fractions using immunocytochemistry with anti-breast cancer monoclonal antibodies and reverse transcriptase polymerase chain reaction (RT-PCR) for cytokeratin-19; and, 3. To determine the true incidence of tumor cell contamination of hematopoietic fractions of Stage II/III breast cancer patients with 4-9 axillary lymph nodes. The bulk of our preliminary breast cancer detection data was generated with fresh marrow and PBPC specimens obtained from University of Colorado breast cancer patients. Over the next two years, the current study will determine the feasibility of conducting similar detection studies with patient specimens shipped overnight from the many cooperative group institutions. If this feasibility study is successful, we will be able to determine the incidence of breast cancer contamination in the hematopoietic cell fractions of patients enrolled in the first two years of the study. We will then seek funding for two additional years to continue to assay the hematopoietic cell specimens of patients enrolled on S9623 for the remainder of the study, which is projected to accrue patients for a total of four years. Clinical outcomes, including disease-free survival rates as well as sites and patterns of relapse, will be correlated with the breast cancer detection assay results. Alternatively, if we are unable to successfully assay the specimens shipped from outside institutions, such additional funding will not be sought. The major aspects of the tumor detection assays which the current feasibility pilot will address include: assessment of the quality of the assays performed on specimens shipped overnight; assessment of outside institution compliance; assessment of the true incidence of breast cancer in the hematopoietic cell fractions of Stage II/III 4-9 nod-positive breast cancer patients; and, will compare the sensitivity of the immunohistochemical and molecular assays for breast cancer.

该项目的具体目的是：1。确定可行性 分析骨髓和外周血祖细胞（PBPC） 乳腺癌患者的分数招收了S9623的存在 恶性细胞； 2。确定定量的可行性 使用的乳腺癌细胞含量和PBPC级分 抗胸腺癌单克隆抗体的免疫细胞化学和 逆转录酶聚合酶链反应（RT-PCR） Cytokeratin-19; 3。确定肿瘤细胞的真实发生率 II/III期乳腺癌造血分数的污染 4-9例腋窝淋巴结的患者。 我们的大部分乳腺癌检测数据是 从大学获得的新鲜骨髓和PBPC标本 科罗拉多州乳腺癌患者。 在接下来的两年中，当前 研究将确定进行类似检测的可行性 使用患者标本的研究从许多 合作集团机构。如果这项可行性研究成功， 我们将能够确定乳腺癌的发生 入学的患者造血细胞分数中的污染 在研究的前两年。 然后，我们将寻求两个 继续分析造血细胞标本的额外几年 剩余的研究的患者在S9623招收的患者中， 预计将使患者总计四年。 临床 结果，包括无病生存率以及场所和 复发模式将与乳腺癌检测有关 测定结果。 另外，如果我们无法成功测定 这些标本从外部机构运来，此类额外资金 不会被寻求。肿瘤检测分析的主要方面 当前的可行性飞行员将解决哪些：评估 在一夜之间运送的标本上执行的测定质量； 评估外部机构合规；真实评估 乳腺癌在造血细胞分数中的发生率 II/III 4-9点头阳性乳腺癌患者；并且，将比较 免疫组织化学和分子测定的敏感性对乳房的敏感性 癌症。